Qiagen's recently-acquired subsidiary, DxS, has struck a deal with drugs giant Pfizer for a companion diagnostic test kit that will be used alongside a new brain tumour drug. Pfizer's PF-04948568 (CDX-110) is an immunotherapy vaccine for treating newly diagnosed glioblastoma ...
Please Login to read the full article.
